BIRC3 and BIRC5: multi‐faceted inhibitors in cancer
Abstract Background The evasion from apoptosis is a common strategy adopted by most tumors, and inhibitors of apoptosis proteins (IAPs) are among the most studied molecular and therapeutic targets. BIRC3 (cellular IAP2) and BIRC5 (survivin) are two of the eight members of the human IAPs family. This...
Main Author: | Raffaele Frazzi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Cell & Bioscience |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13578-020-00521-0 |
Similar Items
-
The expression BIRC6 gene in patients with chronic lymphocytic leukemia – a preliminary study
by: Chomik Piotr, et al.
Published: (2014-09-01) -
Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
by: Fengzhi Li, et al.
Published: (2019-08-01) -
BIRC5 Expression is Regulated in Uterine Epithelium During the Estrous Cycle
by: Minha Cho, et al.
Published: (2020-03-01) -
Expression of anti-apoptothic protein survinin and its gene BIRC5 in primary breast carcinoma as a prognostic factor for the disease
by: E. A. Shlyakhtunov
Published: (2019-02-01) -
Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer
by: Sheng Zhang, et al.
Published: (2019-01-01)